Status:
UNKNOWN
Genetic Determinants of Warfarin Anticoagulation Effect
Lead Sponsor:
Hadassah Medical Organization
Collaborating Sponsors:
United States - Israel Binational Science Foundation
Israel Science Foundation
Conditions:
Venous Thrombosis
Pulmonary Embolism
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The response to warfarin varies greatly among individuals. Some of this variability can be ascribed to genetic polymorphisms in the gene encoding for CYP2C9, the enzyme mediating the metabolism of S w...
Eligibility Criteria
Inclusion
- Patients in whom warfarin is about to be initiated
- Desired therapeutic range \>2 and \<3
Exclusion
- Refusal to participate in the study
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00162435
Start Date
August 1 2002
End Date
December 1 2020
Last Update
June 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel